Pure H2O Bio-Technologies, Inc. Announces New Non-Provisional U.S. Patent Filing for Tetrasilvertetraoxide as Disinfectant Agent for Cryptosporidium.

BOCA RATON, Fla. -- Pure H2O Bio-Technologies, Inc. (Pink Sheets:PHBT) announced today that it filed on July 25, 2006, a Non-Provisional Patent with the United States Patent and Trademark Office, Washington D.C. for Tetrasilver-tetraoxide (TTO) as a Disinfectant Agent for Cryptosporidium. This patent is a follow-up for the Provisional Patent filed on July 28, 2005.

Joseph P. Doxey, President of Pure H20 Bio-Technologies, Inc., said, "The claims, which PHBT accomplished by extensive research and testing included in the patent application, bring the company near to the status, which will give the disinfection system NSF certification."

Pure H2O Bio-Technologies, Inc. developed an improved scientific protocol for this product and engaged Clancy Environmental Consultants, Inc. (CEC) St. Albans, Vermont to perform disinfection studies utilizing TTO as an alternate disinfection process for potable/drinking water.

TTO is an ideal candidate for disinfection of deadly waterborne pathogens such as Cryptosporidium and other protozoans such as Giardia lamblia, whose cysts or oocysts are chlorine-resistant. This current application is a new development in the use of this product for drinking water disinfection within a contained system developed by Pure H2O Bio-Technologies, Inc.

The United States Environmental Protection Agency has stated that adequate product chemistry, efficacy (killing of EPA specified microbial species), environmental fate, toxicology and ecological effects data have been reviewed showing that human exposure from the purposed use is minimal.

It should be noted that very few laboratories in the world have the capability to test for efficacy against Cryptosporidium oocysts. For this reason, PHBT chose Clancy Environmental Consultants, Inc. who is nationally/internationally recognized for their expertise in performing these tests and advising commercial and federal clients. PHBT is confident that claims described in its patents for both microbiology and engineering fields will be verified, thereby placing it in an optimum position to claim a significant market share.

The Company

PHBT is a publicly held company specializing in the manufacturing, design and sale of its unique residential, commercial and hospital point-of-use potable water disinfection systems. These systems are specifically designed to work effectively against water-borne pathogens and remove heavy metals and objectionable biomass.

Note: The foregoing press release contains forward-looking statements that can be identified by such terminology as "expects," "potential," "suggests," "may," "intends," or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results to be materially different from any future results, performance or achievements expressed of implied by such statements. In particular, management's expectations regarding future research, development, and/or commercial results could be affected by, among other things, uncertainties relating to the availability of future financing; unexpected regulatory delays or government regulation generally; the company's ability to obtain or maintain patent and other proprietary intellectual property protection; and completion in general. Forward-looking statements speak only as to the date they were made. The company does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.

For further information regarding PHBT, please visit our website at: http://www.pureh20biotech.com.